# A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

> **NCT04626921** · PHASE2,PHASE3 · COMPLETED · sponsor: **Clene Nanomedicine** · enrollment: 55 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** CNM-Au8

## Key facts

- **NCT ID:** NCT04626921
- **Lead sponsor:** Clene Nanomedicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-22
- **Primary completion:** 2023-05-29
- **Final completion:** 2023-09-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626921, "A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04626921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*